Horizon Pharma (NASDAQ:HZNP) Stock Rating Lowered by BidaskClub
Horizon Pharma (NASDAQ:HZNP) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday, September 18th.
HZNP has been the topic of several other reports. Piper Jaffray Companies set a $25.00 price target on Horizon Pharma and gave the stock a “buy” rating in a research report on Monday, September 17th. Zacks Investment Research lowered Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 17th. Morgan Stanley boosted their price target on Horizon Pharma from $16.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Friday, August 17th. Cantor Fitzgerald lifted their price objective on Horizon Pharma to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, July 25th. Finally, Citigroup downgraded Horizon Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, June 27th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $21.92.
Horizon Pharma stock traded up $0.22 during midday trading on Tuesday, hitting $18.27. 1,083,819 shares of the company were exchanged, compared to its average volume of 1,672,029. The firm has a market capitalization of $3.26 billion, a PE ratio of 15.48, a price-to-earnings-growth ratio of 1.24 and a beta of 1.40. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.63 and a current ratio of 1.70. Horizon Pharma has a fifty-two week low of $12.55 and a fifty-two week high of $21.25.
In other Horizon Pharma news, EVP Geoffrey M. Curtis sold 9,904 shares of Horizon Pharma stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $20.63, for a total transaction of $204,319.52. Following the sale, the executive vice president now directly owns 28,767 shares in the company, valued at approximately $593,463.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.90% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. United Services Automobile Association increased its holdings in shares of Horizon Pharma by 11.0% in the 2nd quarter. United Services Automobile Association now owns 27,036 shares of the biopharmaceutical company’s stock valued at $448,000 after acquiring an additional 2,679 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Horizon Pharma by 25.9% in the 2nd quarter. SG Americas Securities LLC now owns 16,821 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 3,463 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Horizon Pharma by 17.2% in the 2nd quarter. Amalgamated Bank now owns 25,270 shares of the biopharmaceutical company’s stock valued at $418,000 after acquiring an additional 3,711 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in Horizon Pharma by 74.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 3,877 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in Horizon Pharma by 2.2% during the 2nd quarter. Rhumbline Advisers now owns 185,346 shares of the biopharmaceutical company’s stock worth $3,069,000 after buying an additional 3,941 shares during the last quarter. Institutional investors and hedge funds own 87.25% of the company’s stock.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
See Also: The risks of owning bonds
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.